Skip to content
lifestyle.ketodash.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Pharvaris N.V.
Pharvaris: Deucrictibant XR HAE Prophylaxis Study Meets Primary Endpoint
September 8, 2026
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
September 3, 2026
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
August 6, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 21, 2026
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
April 2, 2026
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
March 20, 2026
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
March 11, 2026